can you create a symposium for etiopathogenis , clinical features and complications of hypertensive disorder of pregnancy using recent reasearch article

Asking for Preferences
Reading File
Searching PubMed

"hypertensive disorders of pregnancy" AND "etiopathogenesis"

Searching PubMed

"preeclampsia" AND "pathophysiology" AND "placenta"

Searching PubMed

"preeclampsia" AND "complications" AND "maternal fetal"

Finding Sources
Reading Article

PMID: 38674114

Searching PubMed

"preeclampsia" AND "HELLP syndrome" AND "eclampsia"

Searching PubMed

"preeclampsia" AND "sFlt1" AND "PlGF" AND "biomarker"

Reading File
Reading File
Reading Article

PMID: 41293035

Reading Article

PMID: 39949098

Reading File
Reading File
Reading Article

PMID: 40399152

Reading File
Finding Sources
Reading File
Running Command

mkdir -p /home/daytona/workspace/hdp-symposium && ls /home/daytona/workspace/hdp…

Writing File

~/hdp-symposium/build.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = 'LAYOUT_16x9';
pres.author = 'Symposium';
pres.title = 'Hypertensive Disorders of Pregnancy';

// ─── COLOUR PALETTE ───────────────────────────────────────────────
const DEEP_NAVY   = "0D2137";   // dominant background
const TEAL        = "0A7E8C";   // accent headings / shapes
const AMBER       = "E8A020";   // highlight accent
const WHITE       = "FFFFFF";
const LIGHT_GREY  = "D8E4EC";
const SOFT_BLUE   = "1B4F72";   // secondary background
const DANGER_RED  = "C0392B";   // complications / severity
const TEXT_DARK   = "1A2740";
const MINT        = "17A589";   // positive/normal
const SLIDE_BG    = "F0F4F8";   // light slide backgrounds

// ─── HELPER FUNCTIONS ─────────────────────────────────────────────
function addDarkSlide(pres, bg) {
  const s = pres.addSlide();
  s.background = { color: bg || DEEP_NAVY };
  return s;
}

function addLightSlide(pres) {
  const s = pres.addSlide();
  s.background = { color: SLIDE_BG };
  return s;
}

function sectionBar(slide, text, color) {
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: color || TEAL } });
  slide.addText(text, { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });
}

function accentLine(slide, y, color) {
  slide.addShape(pres.ShapeType.rect, { x: 0.3, y: y, w: 0.08, h: 0.35, fill: { color: color || AMBER } });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 1 — TITLE SLIDE
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);

  // Top decorative bar
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.18, fill: { color: TEAL } });
  // Bottom bar
  s.addShape(pres.ShapeType.rect, { x: 0, y: 5.25, w: 10, h: 0.375, fill: { color: SOFT_BLUE } });
  // Amber accent strip
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0.18, w: 0.12, h: 5.07, fill: { color: AMBER } });

  // Decorative circle
  s.addShape(pres.ShapeType.ellipse, { x: 7.2, y: 0.8, w: 2.5, h: 2.5, fill: { color: TEAL }, line: { color: AMBER, width: 3 } });
  s.addText("HDP", { x: 7.2, y: 1.4, w: 2.5, h: 1.3, fontSize: 36, bold: true, color: WHITE, align: "center", valign: "middle" });

  s.addText("HYPERTENSIVE DISORDERS\nOF PREGNANCY", {
    x: 0.5, y: 0.6, w: 6.5, h: 1.6,
    fontSize: 32, bold: true, color: WHITE, align: "left",
    charSpacing: 2, breakLine: false
  });
  s.addText("Etiopathogenesis • Clinical Features • Complications", {
    x: 0.5, y: 2.3, w: 6.5, h: 0.6,
    fontSize: 16, color: AMBER, italic: true, align: "left"
  });
  s.addText("A Symposium for Postgraduate Residents", {
    x: 0.5, y: 3.0, w: 6.5, h: 0.45,
    fontSize: 13, color: LIGHT_GREY, align: "left"
  });
  s.addText("Based on ACOG Guidelines & Recent Systematic Reviews (2024–2026)", {
    x: 0.5, y: 3.5, w: 6.5, h: 0.45,
    fontSize: 11, color: LIGHT_GREY, italic: true, align: "left"
  });
  s.addText("Vera-Ponce VJ et al., Front Reprod Health 2025  |  Chiang YT et al., Int J Mol Sci 2024  |  Huang W et al., Curr Cardiol Rev 2025", {
    x: 0.2, y: 5.28, w: 9.6, h: 0.3,
    fontSize: 8, color: LIGHT_GREY, align: "left"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 2 — SYMPOSIUM AGENDA / OVERVIEW
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "SYMPOSIUM OVERVIEW", DEEP_NAVY);

  s.addText("Session Outline", { x: 0.3, y: 0.65, w: 9.4, h: 0.5, fontSize: 22, bold: true, color: TEXT_DARK });

  const sessions = [
    { num: "01", title: "Classification & Epidemiology", desc: "ACOG definitions, global burden, risk factors" },
    { num: "02", title: "Etiopathogenesis", desc: "Two-stage model, trophoblast dysfunction, angiogenic imbalance, molecular mechanisms" },
    { num: "03", title: "Clinical Features & Diagnosis", desc: "Gestational HTN, preeclampsia, eclampsia, HELLP — diagnostic criteria" },
    { num: "04", title: "Complications", desc: "Maternal organ involvement, fetal complications, long-term sequelae" },
    { num: "05", title: "Recent Evidence & Biomarkers", desc: "sFlt-1/PlGF, heparan sulfate, genetic & epigenetic markers (2024–2026 data)" },
    { num: "06", title: "Management Pearls", desc: "Acute antihypertensives, MgSO₄, delivery timing, prevention" },
  ];

  sessions.forEach((sess, i) => {
    const col = i < 3 ? 0 : 1;
    const row = i % 3;
    const x = col === 0 ? 0.3 : 5.2;
    const y = 1.25 + row * 1.3;

    s.addShape(pres.ShapeType.rect, { x, y, w: 4.6, h: 1.1, fill: { color: col === 0 ? "E8F4FC" : "EEF8F7" }, line: { color: col === 0 ? TEAL : MINT, width: 1.5 } });
    s.addShape(pres.ShapeType.rect, { x, y, w: 0.5, h: 1.1, fill: { color: col === 0 ? TEAL : MINT } });
    s.addText(sess.num, { x, y: y + 0.35, w: 0.5, h: 0.4, fontSize: 14, bold: true, color: WHITE, align: "center" });
    s.addText(sess.title, { x: x + 0.6, y: y + 0.05, w: 3.9, h: 0.4, fontSize: 12, bold: true, color: TEXT_DARK });
    s.addText(sess.desc, { x: x + 0.6, y: y + 0.48, w: 3.9, h: 0.55, fontSize: 9.5, color: "4A5568", italic: true });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 3 — CLASSIFICATION
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "01  |  CLASSIFICATION (ACOG 2020)", DEEP_NAVY);

  s.addText("ACOG Classification of Hypertensive Disorders of Pregnancy", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.45, fontSize: 18, bold: true, color: TEXT_DARK
  });

  const classes = [
    { label: "Gestational\nHypertension", color: "4A90D9", desc: "BP ≥140/90 mmHg at ≥20 weeks\nNo proteinuria / organ dysfunction\nOccurs in 6–17% of nulliparous women" },
    { label: "Preeclampsia\n± Severe Features", color: TEAL, desc: "BP ≥140/90 + proteinuria OR organ dysfunction\nSevere: BP ≥160/110 or end-organ damage\nAffects 4.43% globally (Vera-Ponce 2025)" },
    { label: "Eclampsia", color: AMBER, desc: "New-onset seizures in preeclamptic patient\nGlobal prevalence: 0.43%\n1 in 2000–3000 deliveries in high-resource settings" },
    { label: "HELLP\nSyndrome", color: DANGER_RED, desc: "Hemolysis + Elevated Liver enzymes\n+ Low Platelets (<100,000/µL)\nGlobal prevalence: 0.39%" },
    { label: "Superimposed\nPreeclampsia", color: SOFT_BLUE, desc: "Preeclampsia on chronic hypertension\nHighest PPCM risk (OR 5.77)\nHardest to diagnose clinically" },
    { label: "Chronic\nHypertension", color: "7B8D8E", desc: "BP ≥140/90 before 20 weeks\nor persisting >12 weeks postpartum\nOR pre-existing diagnosis" },
  ];

  classes.forEach((cl, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.25 + col * 3.2;
    const y = 1.2 + row * 2.1;
    s.addShape(pres.ShapeType.rect, { x, y, w: 3.0, h: 0.5, fill: { color: cl.color } });
    s.addText(cl.label, { x, y, w: 3.0, h: 0.5, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addShape(pres.ShapeType.rect, { x, y: y + 0.5, w: 3.0, h: 1.5, fill: { color: WHITE }, line: { color: cl.color, width: 1.5 } });
    s.addText(cl.desc, { x: x + 0.1, y: y + 0.58, w: 2.8, h: 1.35, fontSize: 9.5, color: TEXT_DARK });
  });

  s.addText("Source: ACOG Practice Bulletin 222 (2020) | Vera-Ponce VJ et al., Front Reprod Health 2025 (PMID: 41293035)", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 4 — EPIDEMIOLOGY
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, SOFT_BLUE);

  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("01  |  EPIDEMIOLOGY & GLOBAL BURDEN", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  s.addText("Global Prevalence — Meta-analysis of 70 studies (Vera-Ponce et al., 2025)", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.45, fontSize: 14, bold: true, color: AMBER
  });

  const stats = [
    { val: "4.43%", label: "Preeclampsia\n(95% CI: 3.73–5.20)", color: TEAL },
    { val: "0.43%", label: "Eclampsia\n(95% CI: 0.19–0.76)", color: AMBER },
    { val: "0.39%", label: "HELLP Syndrome\n(95% CI: 0.16–0.72)", color: DANGER_RED },
    { val: "5–7%", label: "All HDP\nper pregnancy", color: MINT },
  ];

  stats.forEach((st, i) => {
    const x = 0.3 + i * 2.35;
    s.addShape(pres.ShapeType.ellipse, { x, y: 1.2, w: 2.0, h: 2.0, fill: { color: st.color } });
    s.addText(st.val, { x, y: 1.55, w: 2.0, h: 0.7, fontSize: 24, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addText(st.label, { x, y: 2.25, w: 2.0, h: 0.8, fontSize: 9, color: WHITE, align: "center" });
  });

  s.addText("Key Risk Factors", { x: 0.3, y: 3.3, w: 9.4, h: 0.4, fontSize: 13, bold: true, color: AMBER });

  const risks = [
    "Nulliparity", "Prior h/o preeclampsia (8× risk)", "Chronic hypertension",
    "Non-Hispanic Black women", "Obesity (BMI >30)", "Multiple gestation",
    "Age extremes (<18 or >35)", "Family history", "Diabetes / Renal disease"
  ];

  const cols = [risks.slice(0, 3), risks.slice(3, 6), risks.slice(6, 9)];
  cols.forEach((col, ci) => {
    col.forEach((risk, ri) => {
      s.addShape(pres.ShapeType.rect, { x: 0.3 + ci * 3.2, y: 3.75 + ri * 0.38, w: 0.25, h: 0.28, fill: { color: AMBER } });
      s.addText(risk, { x: 0.65 + ci * 3.2, y: 3.75 + ri * 0.38, w: 2.8, h: 0.28, fontSize: 10, color: WHITE });
    });
  });

  s.addText("Vera-Ponce VJ et al. Front Reprod Health. 2025. PMID: 41293035", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: LIGHT_GREY, italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 5 — ETIOPATHOGENESIS: TWO-STAGE MODEL
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "02  |  ETIOPATHOGENESIS: THE TWO-STAGE MODEL", TEAL);

  s.addText("The Two-Stage Model of Preeclampsia", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.45, fontSize: 18, bold: true, color: TEXT_DARK
  });

  // Stage 1 box
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.15, w: 4.1, h: 3.9, fill: { color: "E3F2FD" }, line: { color: TEAL, width: 2 } });
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.15, w: 4.1, h: 0.5, fill: { color: TEAL } });
  s.addText("STAGE 1  (Placental)", { x: 0.3, y: 1.15, w: 4.1, h: 0.5, fontSize: 13, bold: true, color: WHITE, align: "center", valign: "middle" });
  s.addText("8–18 Weeks Gestation", { x: 0.3, y: 1.7, w: 4.1, h: 0.35, fontSize: 10, color: TEAL, bold: true, align: "center" });

  const stage1 = [
    "Failure of extravillous trophoblast invasion",
    "Defective spiral artery remodeling",
    "Shallow invasion → high-resistance uteroplacental circulation",
    "Placental ischemia & oxidative stress",
    "↑ Heparan sulfate release from damaged syncytiotrophoblast (Gómez-Gutiérrez 2026)",
    "Faulty endovascular remodeling → ↑ sFlt-1 & sEng production"
  ];
  stage1.forEach((pt, i) => {
    s.addShape(pres.ShapeType.rect, { x: 0.45, y: 2.1 + i * 0.44, w: 0.2, h: 0.22, fill: { color: TEAL } });
    s.addText(pt, { x: 0.75, y: 2.08 + i * 0.44, w: 3.5, h: 0.38, fontSize: 9.5, color: TEXT_DARK });
  });

  // Arrow
  s.addShape(pres.ShapeType.rect, { x: 4.6, y: 2.85, w: 0.8, h: 0.18, fill: { color: AMBER } });
  s.addText("→", { x: 4.55, y: 2.6, w: 0.9, h: 0.6, fontSize: 28, bold: true, color: AMBER, align: "center" });
  s.addText("triggers", { x: 4.5, y: 3.05, w: 1.0, h: 0.3, fontSize: 9, color: AMBER, align: "center", italic: true });

  // Stage 2 box
  s.addShape(pres.ShapeType.rect, { x: 5.6, y: 1.15, w: 4.1, h: 3.9, fill: { color: "FFF3E0" }, line: { color: AMBER, width: 2 } });
  s.addShape(pres.ShapeType.rect, { x: 5.6, y: 1.15, w: 4.1, h: 0.5, fill: { color: AMBER } });
  s.addText("STAGE 2  (Maternal Syndrome)", { x: 5.6, y: 1.15, w: 4.1, h: 0.5, fontSize: 13, bold: true, color: WHITE, align: "center", valign: "middle" });
  s.addText(">20 Weeks — Clinical Manifestation", { x: 5.6, y: 1.7, w: 4.1, h: 0.35, fontSize: 10, color: AMBER, bold: true, align: "center" });

  const stage2 = [
    "↑ Anti-angiogenic factors: sFlt-1 & soluble endoglin (sEng)",
    "Sequestration of VEGF & PlGF → endothelial dysfunction",
    "Generalized vasospasm & hypertension",
    "Systemic inflammatory response & complement activation",
    "Multi-organ endothelial injury",
    "Hemoconcentration & ↑ vascular permeability → proteinuria"
  ];
  stage2.forEach((pt, i) => {
    s.addShape(pres.ShapeType.rect, { x: 5.75, y: 2.1 + i * 0.44, w: 0.2, h: 0.22, fill: { color: AMBER } });
    s.addText(pt, { x: 6.05, y: 2.08 + i * 0.44, w: 3.5, h: 0.38, fontSize: 9.5, color: TEXT_DARK });
  });

  s.addText("Goldman-Cecil Medicine | Chiang YT et al., Int J Mol Sci 2024 (PMID: 38674114) | Gómez-Gutiérrez AM et al., Placenta 2026 (PMID: 40399152)", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 6 — MOLECULAR MECHANISMS
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("02  |  MOLECULAR MECHANISMS OF PREECLAMPSIA", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  s.addText("Systematic Review — Chiang YT, Seow KM, Chen KH. Int J Mol Sci 2024", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.35, fontSize: 11, bold: true, color: AMBER
  });

  const mechanisms = [
    {
      title: "Fetal Microchimerism",
      color: TEAL,
      points: ["Fetal cells persist in maternal circulation", "Mechanistic link between placental dysfunction & maternal syndrome", "Modulates immune tolerance"]
    },
    {
      title: "Angiogenic Imbalance",
      color: AMBER,
      points: ["↑ sFlt-1 sequesters free VEGF & PlGF", "↑ Soluble endoglin → anti-TGF-β activity", "Net result: endothelial injury & hypertension"]
    },
    {
      title: "Immune Dysregulation",
      color: MINT,
      points: ["↓ Soluble HLA-G → impaired maternal-fetal tolerance", "Complement system activation", "Pro-inflammatory cytokine surge (IL-6, TNF-α)"]
    },
    {
      title: "Epigenetic / RNA Regulation",
      color: "A569BD",
      points: ["CircRNA_06354 — early-onset PE via hsa-miR-92a-3p/VEGF-A", "miR-519d & miR-517-5p — dysregulate trophoblast function", "lncRNAs (IGFBP1, EGFR-AS1) — impair angiogenesis"]
    },
    {
      title: "Extracellular Matrix Changes",
      color: DANGER_RED,
      points: ["↑ Heparan sulfate (HS) in maternal serum", "SMD 1.2 increase in PE vs. normal pregnancy (Gómez-Gutiérrez 2026)", "Syncytiotrophoblast damage releases HS into blood"]
    },
    {
      title: "HIF-1α Dysregulation",
      color: SOFT_BLUE,
      points: ["Hypoxia-inducible factor 1-α upregulated", "Placental hypoxia → abnormal gene expression", "MMP & endothelin dysregulation → defective invasion"]
    }
  ];

  mechanisms.forEach((mech, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.2 + col * 3.27;
    const y = 1.1 + row * 2.2;

    s.addShape(pres.ShapeType.rect, { x, y, w: 3.05, h: 0.42, fill: { color: mech.color } });
    s.addText(mech.title, { x, y, w: 3.05, h: 0.42, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addShape(pres.ShapeType.rect, { x, y: y + 0.42, w: 3.05, h: 1.65, fill: { color: "1A2F45" }, line: { color: mech.color, width: 1 } });
    mech.points.forEach((pt, pi) => {
      s.addText("• " + pt, { x: x + 0.1, y: y + 0.5 + pi * 0.48, w: 2.85, h: 0.42, fontSize: 9.5, color: LIGHT_GREY });
    });
  });

  s.addText("Chiang YT et al., Int J Mol Sci 2024 (PMID: 38674114)  |  Gómez-Gutiérrez AM et al., Placenta 2026 (PMID: 40399152)", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: LIGHT_GREY, italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 7 — RISK FACTORS (DEEPER)
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "02  |  PREDISPOSING FACTORS & IMMUNOLOGICAL BASIS", TEAL);

  s.addText("Why Does Stage 1 Fail?", { x: 0.3, y: 0.65, w: 9.4, h: 0.45, fontSize: 18, bold: true, color: TEXT_DARK });

  // Left column: immunological
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.2, w: 4.3, h: 4.1, fill: { color: "E8F8F5" }, line: { color: MINT, width: 1.5 } });
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.2, w: 4.3, h: 0.45, fill: { color: MINT } });
  s.addText("IMMUNOLOGICAL FACTORS", { x: 0.3, y: 1.2, w: 4.3, h: 0.45, fontSize: 12, bold: true, color: WHITE, align: "center", valign: "middle" });
  const imm = [
    "Limited exposure to paternal antigens → impaired tolerance",
    "Primipaternity / new partner → ↑ risk",
    "NK cell dysfunction in decidua",
    "Th1/Th2 imbalance → excess inflammatory response",
    "↓ Regulatory T cells (Tregs) at maternal-fetal interface",
    "Complement activation (C3, C5a) → trophoblast injury",
    "HLA-G reduction → impaired immune tolerance (Chiang 2024)"
  ];
  imm.forEach((pt, i) => {
    accentLine(s, 1.75 + i * 0.48, MINT);
    s.addText(pt, { x: 0.55, y: 1.75 + i * 0.48, w: 3.9, h: 0.42, fontSize: 9.5, color: TEXT_DARK });
  });

  // Right column: genetic
  s.addShape(pres.ShapeType.rect, { x: 5.3, y: 1.2, w: 4.3, h: 4.1, fill: { color: "F0F0FB" }, line: { color: SOFT_BLUE, width: 1.5 } });
  s.addShape(pres.ShapeType.rect, { x: 5.3, y: 1.2, w: 4.3, h: 0.45, fill: { color: SOFT_BLUE } });
  s.addText("GENETIC & HORMONAL FACTORS", { x: 5.3, y: 1.2, w: 4.3, h: 0.45, fontSize: 12, bold: true, color: WHITE, align: "center", valign: "middle" });
  const gen = [
    "Polygenic inheritance — maternal & fetal genome interactions",
    "FLT1 gene variants → excess sFlt-1 production",
    "AGT (angiotensinogen) polymorphisms",
    "↓ PPAR-γ expression → impaired trophoblast differentiation",
    "↑ Endothelin-1 (ET-1) → vasoconstriction",
    "Low calcium intake → ↑ PTH → ↑ vascular tone",
    "Dysregulated renin-angiotensin-aldosterone system"
  ];
  gen.forEach((pt, i) => {
    accentLine(s, 1.75 + i * 0.48, SOFT_BLUE);
    s.addText(pt, { x: 5.55, y: 1.75 + i * 0.48, w: 3.9, h: 0.42, fontSize: 9.5, color: TEXT_DARK });
  });

  s.addText("Goldman-Cecil Medicine, 2024  |  Chiang YT et al., Int J Mol Sci 2024", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 8 — CLINICAL FEATURES: GESTATIONAL HTN & PREECLAMPSIA
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "03  |  CLINICAL FEATURES — GESTATIONAL HYPERTENSION & PREECLAMPSIA", DEEP_NAVY);

  s.addText("Diagnostic Criteria (ACOG Practice Bulletin 222, 2020)", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.4, fontSize: 15, bold: true, color: TEXT_DARK
  });

  // Gestational HTN
  s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.1, w: 4.4, h: 4.15, fill: { color: "EBF5FB" }, line: { color: "4A90D9", width: 2 } });
  s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.1, w: 4.4, h: 0.5, fill: { color: "4A90D9" } });
  s.addText("GESTATIONAL HYPERTENSION", { x: 0.2, y: 1.1, w: 4.4, h: 0.5, fontSize: 12, bold: true, color: WHITE, align: "center", valign: "middle" });
  const gHtn = [
    { bold: "BP:", text: " ≥140/90 mmHg on 2 occasions ≥4h apart" },
    { bold: "Onset:", text: " ≥20 weeks gestation" },
    { bold: "Absence of:", text: " proteinuria, organ dysfunction" },
    { bold: "Incidence:", text: " 6–17% nulliparous, 2–4% multiparous" },
    { bold: "Progression:", text: " ~25% progress to preeclampsia" },
    { bold: "Resolution:", text: " BP normalises by 12 weeks postpartum" },
    { bold: "Chronic HTN if:", text: " persists >12 weeks postpartum" },
  ];
  gHtn.forEach((item, i) => {
    s.addText([
      { text: item.bold, options: { bold: true, color: "4A90D9" } },
      { text: item.text, options: { color: TEXT_DARK } }
    ], { x: 0.4, y: 1.72 + i * 0.48, w: 4.0, h: 0.42, fontSize: 10 });
  });

  // Preeclampsia
  s.addShape(pres.ShapeType.rect, { x: 5.4, y: 1.1, w: 4.4, h: 4.15, fill: { color: "E8F8F5" }, line: { color: TEAL, width: 2 } });
  s.addShape(pres.ShapeType.rect, { x: 5.4, y: 1.1, w: 4.4, h: 0.5, fill: { color: TEAL } });
  s.addText("PREECLAMPSIA", { x: 5.4, y: 1.1, w: 4.4, h: 0.5, fontSize: 12, bold: true, color: WHITE, align: "center", valign: "middle" });
  const pe = [
    { bold: "BP:", text: " ≥140/90 mmHg at ≥20 weeks" },
    { bold: "PLUS proteinuria:", text: " ≥300 mg/24h or P:Cr ratio ≥0.3" },
    { bold: "OR", text: " end-organ dysfunction (see next slide)" },
    { bold: "Early-onset:", text: " <34 weeks (more severe, placental)" },
    { bold: "Late-onset:", text: " ≥34 weeks (more common, maternal)" },
    { bold: "Hemoconcentration:", text: " hallmark finding" },
    { bold: "Systemic:", text: " affects virtually every organ system" },
  ];
  pe.forEach((item, i) => {
    s.addText([
      { text: item.bold, options: { bold: true, color: TEAL } },
      { text: item.text, options: { color: TEXT_DARK } }
    ], { x: 5.6, y: 1.72 + i * 0.48, w: 4.0, h: 0.42, fontSize: 10 });
  });

  s.addText("Goldman-Cecil Medicine 2024  |  Creasy & Resnik's Maternal-Fetal Medicine", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 9 — SEVERE FEATURES / ECLAMPSIA / HELLP
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "03  |  SEVERE FEATURES, ECLAMPSIA & HELLP SYNDROME", DANGER_RED);

  s.addText("Criteria for Severe Features (ACOG 222, 2020)", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.4, fontSize: 15, bold: true, color: DANGER_RED
  });

  // Severe features table
  const headers = ["System", "Criterion", "Threshold"];
  const rows = [
    ["Cardiovascular", "Systolic BP", "≥160 mmHg on 2 occasions ≥4h apart"],
    ["Cardiovascular", "Diastolic BP", "≥110 mmHg on 2 occasions ≥4h apart"],
    ["Haematology", "Thrombocytopenia", "Platelet count <100,000/µL"],
    ["Hepatic", "Liver enzymes", ">2× upper limit of normal"],
    ["Hepatic", "Pain", "Severe RUQ or epigastric pain unresponsive to medication"],
    ["Renal", "Serum creatinine", ">1.1 mg/dL or doubling of baseline"],
    ["Pulmonary", "Pulmonary oedema", "New-onset pulmonary oedema"],
    ["Neurological", "Headache", "New-onset severe headache unresponsive to analgesia"],
    ["Neurological", "Visual", "Blurred vision, scotoma, photopsia"],
  ];

  const colW = [1.6, 2.2, 5.5];
  const colX = [0.2, 1.85, 4.1];
  // Header
  headers.forEach((h, i) => {
    s.addShape(pres.ShapeType.rect, { x: colX[i], y: 1.1, w: colW[i], h: 0.38, fill: { color: DANGER_RED } });
    s.addText(h, { x: colX[i], y: 1.1, w: colW[i], h: 0.38, fontSize: 10, bold: true, color: WHITE, align: "center", valign: "middle" });
  });
  rows.forEach((row, ri) => {
    const bg = ri % 2 === 0 ? "FFF5F5" : WHITE;
    row.forEach((cell, ci) => {
      s.addShape(pres.ShapeType.rect, { x: colX[ci], y: 1.48 + ri * 0.36, w: colW[ci], h: 0.36, fill: { color: bg }, line: { color: "E0E0E0", width: 0.5 } });
      s.addText(cell, { x: colX[ci] + 0.05, y: 1.48 + ri * 0.36, w: colW[ci] - 0.1, h: 0.36, fontSize: 9, color: TEXT_DARK, valign: "middle" });
    });
  });

  // Eclampsia & HELLP boxes at bottom
  s.addShape(pres.ShapeType.rect, { x: 0.2, y: 4.8, w: 4.6, h: 0.72, fill: { color: "FFFDE7" }, line: { color: AMBER, width: 1.5 } });
  s.addText([
    { text: "ECLAMPSIA: ", options: { bold: true, color: AMBER } },
    { text: "New-onset tonic-clonic/focal seizures. Rule out other causes. May be preceded by severe headache, visual disturbances. PRES on MRI (occipital/parietal).", options: { color: TEXT_DARK } }
  ], { x: 0.3, y: 4.83, w: 4.4, h: 0.66, fontSize: 9.5 });

  s.addShape(pres.ShapeType.rect, { x: 5.3, y: 4.8, w: 4.4, h: 0.72, fill: { color: "FFF0F0" }, line: { color: DANGER_RED, width: 1.5 } });
  s.addText([
    { text: "HELLP SYNDROME: ", options: { bold: true, color: DANGER_RED } },
    { text: "Haemolysis (LDH >600, fragmented RBCs) + LFTs >2× normal + Platelets <100,000/µL. May present WITHOUT hypertension in 20% cases.", options: { color: TEXT_DARK } }
  ], { x: 5.4, y: 4.83, w: 4.2, h: 0.66, fontSize: 9.5 });

  s.addText("Goldman-Cecil Medicine 2024 — Table 221-7  |  ACOG Practice Bulletin 222", {
    x: 0.3, y: 5.56, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 10 — COMPLICATIONS: MATERNAL
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: DANGER_RED } });
  s.addText("04  |  COMPLICATIONS — MATERNAL", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  s.addText("Multi-System Organ Involvement", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.4, fontSize: 16, bold: true, color: AMBER
  });

  const organs = [
    { system: "Cardiovascular", color: DANGER_RED, comps: ["Severe hypertension → hypertensive crisis", "Pulmonary oedema (↑ afterload + ↑ permeability)", "Peripartum cardiomyopathy (PPCM)\nOR 13.33 with severe PE (Huang W 2025)"] },
    { system: "CNS / Neurological", color: "A569BD", comps: ["Eclamptic seizures", "PRES — posterior reversible encephalopathy", "Stroke / intracranial haemorrhage", "Cortical blindness"] },
    { system: "Hepatic", color: AMBER, comps: ["Hepatocellular necrosis", "Subcapsular haematoma → rupture", "HELLP syndrome (0.39% of pregnancies)", "Elevated ALT/AST >2× normal"] },
    { system: "Renal", color: TEAL, comps: ["Acute tubular necrosis", "Glomeruloendotheliosis", "Renal insufficiency (Cr >1.1 mg/dL)", "Oliguria / acute kidney injury"] },
    { system: "Haematological", color: MINT, comps: ["Thrombocytopenia (↓100,000/µL)", "Microangiopathic haemolytic anaemia", "DIC in severe cases", "↑ LDH, ↓ haptoglobin"] },
    { system: "Long-Term Sequelae", color: SOFT_BLUE, comps: ["Chronic HTN in 36.5% after 2–7 yrs", "CVD risk ratio: 2× (8× early-onset PE)", "Stage 2 HTN rates: 25–50% within years", "AHA classifies prior PE as CVD risk factor"] },
  ];

  organs.forEach((org, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.2 + col * 3.27;
    const y = 1.1 + row * 2.3;

    s.addShape(pres.ShapeType.rect, { x, y, w: 3.05, h: 0.4, fill: { color: org.color } });
    s.addText(org.system, { x, y, w: 3.05, h: 0.4, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addShape(pres.ShapeType.rect, { x, y: y + 0.4, w: 3.05, h: 1.78, fill: { color: "142030" }, line: { color: org.color, width: 1 } });
    org.comps.forEach((comp, ci) => {
      s.addText("• " + comp, { x: x + 0.1, y: y + 0.48 + ci * 0.42, w: 2.85, h: 0.38, fontSize: 9, color: LIGHT_GREY });
    });
  });

  s.addText("Creasy & Resnik MFM | Huang W et al., Curr Cardiol Rev 2025 (PMID: 39949098)  |  Goldman-Cecil Medicine 2024", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: LIGHT_GREY, italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 11 — COMPLICATIONS: FETAL & PERIPARTUM CARDIOMYOPATHY
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "04  |  FETAL COMPLICATIONS & PERIPARTUM CARDIOMYOPATHY", DANGER_RED);

  s.addText("Fetal & Neonatal Complications", {
    x: 0.3, y: 0.65, w: 5.5, h: 0.4, fontSize: 16, bold: true, color: TEXT_DARK
  });

  const fetalComps = [
    { title: "Placental Insufficiency", desc: "Defective spiral artery remodeling → uteroplacental ischaemia → fetal hypoxia" },
    { title: "FGR / IUGR", desc: "Fetal growth restriction — especially in early-onset PE (<34 wks)" },
    { title: "Oligohydramnios", desc: "Reduced renal perfusion → decreased amniotic fluid volume" },
    { title: "Prematurity", desc: "Iatrogenic preterm birth — delivery the only cure for PE" },
    { title: "Placental Abruption", desc: "↑ risk with severe PE; may cause fetal distress or demise" },
    { title: "Perinatal Mortality", desc: "Leading cause of perinatal death in HIC; higher in LMIC" },
  ];

  fetalComps.forEach((fc, i) => {
    const y = 1.12 + i * 0.58;
    s.addShape(pres.ShapeType.rect, { x: 0.2, y, w: 1.9, h: 0.44, fill: { color: DANGER_RED } });
    s.addText(fc.title, { x: 0.2, y, w: 1.9, h: 0.44, fontSize: 9.5, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addShape(pres.ShapeType.rect, { x: 2.15, y, w: 3.5, h: 0.44, fill: { color: "FFF5F5" }, line: { color: DANGER_RED, width: 0.5 } });
    s.addText(fc.desc, { x: 2.25, y: y + 0.03, w: 3.3, h: 0.38, fontSize: 9.5, color: TEXT_DARK, valign: "middle" });
  });

  // PPCM spotlight box
  s.addShape(pres.ShapeType.rect, { x: 5.9, y: 0.65, w: 3.85, h: 4.55, fill: { color: "FFF8E1" }, line: { color: AMBER, width: 2 } });
  s.addShape(pres.ShapeType.rect, { x: 5.9, y: 0.65, w: 3.85, h: 0.5, fill: { color: AMBER } });
  s.addText("SPOTLIGHT: HDP & PPCM", { x: 5.9, y: 0.65, w: 3.85, h: 0.5, fontSize: 12, bold: true, color: WHITE, align: "center", valign: "middle" });
  s.addText("Huang W et al., Curr Cardiol Rev 2025\nSystematic Review & Meta-analysis\n13 studies | 11,951 PPCM cases", {
    x: 6.0, y: 1.22, w: 3.65, h: 0.7, fontSize: 9.5, color: "5D4037", italic: true
  });

  const ppcmData = [
    { label: "Severe Preeclampsia", or: "OR 13.33", ci: "(CI: 5.95–29.83)", color: DANGER_RED },
    { label: "Superimposed PE", or: "OR 5.77", ci: "p <0.01", color: "E67E22" },
    { label: "Chronic Hypertension", or: "OR 4.73", ci: "p <0.01", color: AMBER },
    { label: "Preeclampsia", or: "OR 4.70", ci: "p <0.01", color: MINT },
    { label: "Gestational HTN", or: "OR 3.13", ci: "p <0.01", color: TEAL },
  ];

  ppcmData.forEach((item, i) => {
    const y = 2.05 + i * 0.56;
    s.addShape(pres.ShapeType.rect, { x: 6.0, y, w: 1.5, h: 0.44, fill: { color: item.color } });
    s.addText(item.or, { x: 6.0, y, w: 1.5, h: 0.44, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addText(item.label + "\n" + item.ci, { x: 7.58, y, w: 2.0, h: 0.44, fontSize: 9, color: TEXT_DARK });
  });

  s.addText("Clinical Implication: Screen for PPCM in all HDP patients with dyspnoea, orthopnoea, or ↓ exercise tolerance", {
    x: 5.9, y: 4.9, w: 3.85, h: 0.35, fontSize: 9, color: "5D4037", bold: true, align: "center"
  });

  s.addText("Huang W et al., Curr Cardiol Rev 2025 (PMID: 39949098)  |  Creasy & Resnik Maternal-Fetal Medicine", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 12 — NOVEL BIOMARKERS
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, SOFT_BLUE);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: MINT } });
  s.addText("05  |  BIOMARKERS & RECENT EVIDENCE (2024–2026)", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  s.addText("Emerging & Validated Biomarkers for Prediction & Surveillance", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.38, fontSize: 14, bold: true, color: AMBER
  });

  const biomarkers = [
    {
      name: "sFlt-1 / PlGF Ratio",
      status: "Validated",
      statusColor: MINT,
      detail: "Anti-angiogenic imbalance marker. sFlt-1:PlGF <38 rules out PE within 1 week. EMA-approved screening tool. Best predictor for early-onset PE.",
      evidence: "Goldman-Cecil Medicine 2024"
    },
    {
      name: "Heparan Sulfate (HS)",
      status: "Emerging",
      statusColor: AMBER,
      detail: "Released from damaged syncytiotrophoblast & endothelial cells. Meta-analysis shows SMD 1.2 increase in PE vs. normal pregnancy. Higher in early-onset PE.",
      evidence: "Gómez-Gutiérrez AM, Placenta 2026 (PMID: 40399152)"
    },
    {
      name: "Soluble HLA-G",
      status: "Research",
      statusColor: "A569BD",
      detail: "Reduced in preeclampsia. Involved in maternal-fetal immune tolerance. Potential predictor of defective trophoblast invasion.",
      evidence: "Chiang YT, Int J Mol Sci 2024 (PMID: 38674114)"
    },
    {
      name: "MicroRNAs (miRNAs)",
      status: "Research",
      statusColor: "E67E22",
      detail: "CircRNA_06354 → early PE via hsa-miR-92a-3p/VEGF-A pathway. miR-519d & miR-517-5p impair trophoblast function. C19MC cluster dysregulated in PE.",
      evidence: "Chiang YT, Int J Mol Sci 2024 (PMID: 38674114)"
    },
    {
      name: "Soluble Endoglin (sEng)",
      status: "Validated",
      statusColor: MINT,
      detail: "Anti-TGF-β activity → worsens endothelial dysfunction. Elevated before clinical PE onset. Correlates with disease severity.",
      evidence: "Goldman-Cecil Medicine 2024"
    },
    {
      name: "Matrix Metalloproteinases (MMPs)",
      status: "Emerging",
      statusColor: AMBER,
      detail: "MMP-2, MMP-9 dysregulation → defective spiral artery remodeling. Potential early marker for predicting PE onset.",
      evidence: "Chiang YT, Int J Mol Sci 2024"
    },
  ];

  biomarkers.forEach((bm, i) => {
    const col = i % 2;
    const row = Math.floor(i / 2);
    const x = 0.2 + col * 4.9;
    const y = 1.1 + row * 1.5;

    s.addShape(pres.ShapeType.rect, { x, y, w: 4.6, h: 1.35, fill: { color: "1A3045" }, line: { color: bm.statusColor, width: 1.5 } });
    s.addShape(pres.ShapeType.rect, { x, y, w: 2.8, h: 0.38, fill: { color: "1A3045" } });
    s.addText(bm.name, { x: x + 0.1, y: y + 0.05, w: 2.8, h: 0.3, fontSize: 11, bold: true, color: WHITE });
    s.addShape(pres.ShapeType.rect, { x: x + 3.0, y: y + 0.06, w: 1.45, h: 0.27, fill: { color: bm.statusColor } });
    s.addText(bm.status, { x: x + 3.0, y: y + 0.06, w: 1.45, h: 0.27, fontSize: 9, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addText(bm.detail, { x: x + 0.1, y: y + 0.42, w: 4.35, h: 0.65, fontSize: 9, color: LIGHT_GREY });
    s.addText(bm.evidence, { x: x + 0.1, y: y + 1.1, w: 4.35, h: 0.22, fontSize: 8, color: AMBER, italic: true });
  });

  s.addText("Gómez-Gutiérrez AM, Placenta 2026 (PMID: 40399152)  |  Chiang YT, Int J Mol Sci 2024 (PMID: 38674114)", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: LIGHT_GREY, italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 13 — MANAGEMENT PEARLS
// ═══════════════════════════════════════════════════════════════════
{
  const s = addLightSlide(pres);
  sectionBar(s, "06  |  MANAGEMENT PEARLS FOR POSTGRADUATE RESIDENTS", DEEP_NAVY);

  s.addText("Key Management Principles", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.4, fontSize: 16, bold: true, color: TEXT_DARK
  });

  // Antihypertensives table
  s.addText("Acute Antihypertensive Therapy (BP ≥160/110 mmHg)", {
    x: 0.3, y: 1.1, w: 5.5, h: 0.35, fontSize: 12, bold: true, color: TEAL
  });

  const ahHeaders = ["Drug", "Route", "Dose", "Notes"];
  const ahColW = [1.3, 0.7, 2.1, 1.3];
  const ahColX = [0.2, 1.55, 2.3, 4.45];
  ahHeaders.forEach((h, i) => {
    s.addShape(pres.ShapeType.rect, { x: ahColX[i], y: 1.5, w: ahColW[i], h: 0.35, fill: { color: TEAL } });
    s.addText(h, { x: ahColX[i], y: 1.5, w: ahColW[i], h: 0.35, fontSize: 9.5, bold: true, color: WHITE, align: "center", valign: "middle" });
  });

  const ahRows = [
    ["Labetalol", "IV", "20–80 mg q10–30 min (max 300 mg)\nor 1–2 mg/min infusion", "1st line IV, avoid in asthma"],
    ["Hydralazine", "IV", "5–10 mg q 20–40 min\n(max 20 mg)", "Caution: maternal hypotension"],
    ["Nifedipine IR", "PO", "10–20 mg then q 20 min\n(max 180 mg/day)", "Avoid sublingual route"],
  ];

  ahRows.forEach((row, ri) => {
    const bg = ri % 2 === 0 ? "EBF5FB" : WHITE;
    row.forEach((cell, ci) => {
      s.addShape(pres.ShapeType.rect, { x: ahColX[ci], y: 1.85 + ri * 0.58, w: ahColW[ci], h: 0.55, fill: { color: bg }, line: { color: LIGHT_GREY, width: 0.5 } });
      s.addText(cell, { x: ahColX[ci] + 0.04, y: 1.85 + ri * 0.58, w: ahColW[ci] - 0.08, h: 0.55, fontSize: 9, color: TEXT_DARK, valign: "middle" });
    });
  });

  // MgSO4 box
  s.addShape(pres.ShapeType.rect, { x: 0.2, y: 3.6, w: 5.5, h: 1.0, fill: { color: "EFF8FF" }, line: { color: SOFT_BLUE, width: 1.5 } });
  s.addText([
    { text: "MgSO₄ Protocol: ", options: { bold: true, color: SOFT_BLUE } },
    { text: "Loading dose 4–6 g IV over 15–20 min, then 2 g/hr maintenance. Therapeutic range: 4–7 mEq/L. Antidote: Calcium gluconate 1 g IV. Monitor: reflexes, RR, urine output. Cleared by kidney — reduce in renal impairment.", options: { color: TEXT_DARK } }
  ], { x: 0.35, y: 3.65, w: 5.25, h: 0.9, fontSize: 9.5 });

  // Right panel
  s.addShape(pres.ShapeType.rect, { x: 5.9, y: 1.1, w: 3.85, h: 3.55, fill: { color: "F0FFF4" }, line: { color: MINT, width: 1.5 } });
  s.addShape(pres.ShapeType.rect, { x: 5.9, y: 1.1, w: 3.85, h: 0.42, fill: { color: MINT } });
  s.addText("DELIVERY — THE ONLY CURE", { x: 5.9, y: 1.1, w: 3.85, h: 0.42, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });

  const delivery = [
    "PE without severe features at ≥37 weeks → delivery",
    "PE with severe features at ≥34 weeks → delivery",
    "Severe PE <34 wks → consider steroids + stabilise",
    "Eclampsia → IV MgSO₄ then deliver (not emergency CS unless abruption)",
    "HELLP syndrome → delivery regardless of GA",
    "Caesarean NOT mandated by PE/eclampsia alone",
    "Postpartum: continue antihypertensives for ≥72h"
  ];
  delivery.forEach((pt, i) => {
    s.addText("• " + pt, { x: 6.05, y: 1.6 + i * 0.44, w: 3.55, h: 0.4, fontSize: 9.5, color: TEXT_DARK });
  });

  // Prevention bar
  s.addShape(pres.ShapeType.rect, { x: 0.2, y: 4.68, w: 9.55, h: 0.52, fill: { color: AMBER } });
  s.addText("PREVENTION: Low-dose aspirin 81–150 mg/day from 12–28 wks in high-risk women  |  Calcium 1.5–2 g/day in low-calcium populations (Zhu Q, Preg Hypertens 2024)  |  Optimize BMI before pregnancy", {
    x: 0.3, y: 4.7, w: 9.4, h: 0.46, fontSize: 9, color: WHITE, bold: true, align: "center", valign: "middle"
  });

  s.addText("Goldman-Cecil Medicine 2024 — Table 221-6  |  Zhu Q et al., Pregnancy Hypertens 2024 (PMID: 39608269)", {
    x: 0.3, y: 5.32, w: 9.4, h: 0.25, fontSize: 7.5, color: "6B7280", italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 14 — LONG-TERM CONSEQUENCES
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: SOFT_BLUE } });
  s.addText("04  |  LONG-TERM CONSEQUENCES — PREGNANCY AS A STRESS TEST", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  s.addText("Pregnancy reveals subclinical cardiovascular risk — AHA classifies prior PE as an established CVD risk factor", {
    x: 0.3, y: 0.65, w: 9.4, h: 0.38, fontSize: 12, italic: true, color: AMBER
  });

  const longTerm = [
    { outcome: "Chronic\nHypertension", risk: "36.5%", timeframe: "2–7 yrs", rr: "RR ~2–3×", color: DANGER_RED },
    { outcome: "Cardiovascular\nDisease (CVD)", risk: "↑ 2–8×", timeframe: "Within 5 yrs", rr: "CAD, CVA, HF", color: "E67E22" },
    { outcome: "End-Stage\nRenal Disease", risk: "↑ Risk", timeframe: "Long-term", rr: "Glomerular damage", color: TEAL },
    { outcome: "Stage 2 HTN\n(Early-onset PE)", risk: "50%", timeframe: "Post-delivery", rr: "vs <4% controls", color: "A569BD" },
    { outcome: "LV Diastolic\nDysfunction", risk: "↑ Risk", timeframe: "≤10 yrs post-PE", rr: "Silent HF, LV remodelling", color: MINT },
    { outcome: "Future\nDiabetes", risk: "↑ Risk", timeframe: "Long-term", rr: "Metabolic syndrome overlap", color: AMBER },
  ];

  longTerm.forEach((item, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.3 + col * 3.2;
    const y = 1.12 + row * 2.0;

    s.addShape(pres.ShapeType.rect, { x, y, w: 2.95, h: 0.5, fill: { color: item.color } });
    s.addText(item.outcome, { x, y, w: 2.95, h: 0.5, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addShape(pres.ShapeType.rect, { x, y: y + 0.5, w: 2.95, h: 1.38, fill: { color: "1A2F45" }, line: { color: item.color, width: 1 } });
    s.addText(item.risk, { x, y: y + 0.6, w: 2.95, h: 0.5, fontSize: 22, bold: true, color: item.color, align: "center" });
    s.addText(item.timeframe, { x, y: y + 1.1, w: 2.95, h: 0.28, fontSize: 9.5, color: LIGHT_GREY, align: "center" });
    s.addText(item.rr, { x, y: y + 1.38, w: 2.95, h: 0.28, fontSize: 9, color: AMBER, align: "center", italic: true });
  });

  // Clinical message
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 5.12, w: 9.4, h: 0.38, fill: { color: TEAL } });
  s.addText("Clinical Pearl: All women with prior HDP require postnatal CVD risk counselling, BP monitoring, and lifestyle modification advice", {
    x: 0.3, y: 5.12, w: 9.4, h: 0.38, fontSize: 10, color: WHITE, bold: true, align: "center", valign: "middle"
  });
  s.addText("Creasy & Resnik Maternal-Fetal Medicine, 9e  |  AHA 2021 Guidelines", {
    x: 0.3, y: 5.53, w: 9.4, h: 0.25, fontSize: 7.5, color: LIGHT_GREY, italic: true
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 15 — REFERENCES
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("REFERENCES & FURTHER READING", { x: 0.2, y: 0.05, w: 9.6, h: 0.45, fontSize: 14, bold: true, color: WHITE, valign: "middle" });

  const refs = [
    "1. Vera-Ponce VJ et al. Global prevalence of preeclampsia, eclampsia, and HELLP syndrome: a systematic review and meta-analysis. Front Reprod Health. 2025. PMID: 41293035",
    "2. Chiang YT, Seow KM, Chen KH. The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms. Int J Mol Sci. 2024;25(8):4532. PMID: 38674114",
    "3. Gómez-Gutiérrez AM et al. Maternal serum heparan sulfate in preeclampsia pathophysiology: Insights from a systematic review and meta-analysis. Placenta. 2026. PMID: 40399152",
    "4. Huang W et al. Association of Hypertensive Disorders of Pregnancy and their Clinical Features with Peripartum Cardiomyopathy: A Systematic Review and Meta-analysis. Curr Cardiol Rev. 2025. PMID: 39949098",
    "5. Zhu Q et al. Effectiveness of calcium supplementation in the prevention of gestational hypertension: A systematic review and meta-analysis. Pregnancy Hypertens. 2024. PMID: 39608269",
    "6. Goldman-Cecil Medicine International Edition. 2 Volume Set. 27th ed. Philadelphia: Elsevier; 2024.",
    "7. Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice. 9th ed. Philadelphia: Elsevier; 2022.",
    "8. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:237–260.",
    "9. American Heart Association. Hypertension in Pregnancy — Established Risk Factor for CVD. AHA Scientific Statement, 2021.",
  ];

  refs.forEach((ref, i) => {
    s.addShape(pres.ShapeType.rect, { x: 0.3, y: 0.65 + i * 0.52, w: 0.08, h: 0.3, fill: { color: AMBER } });
    s.addText(ref, { x: 0.48, y: 0.65 + i * 0.52, w: 9.3, h: 0.46, fontSize: 8.8, color: LIGHT_GREY });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 16 — CLOSING / TAKE-HOME MESSAGES
// ═══════════════════════════════════════════════════════════════════
{
  const s = addDarkSlide(pres, DEEP_NAVY);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.18, fill: { color: TEAL } });
  s.addShape(pres.ShapeType.rect, { x: 0, y: 5.25, w: 10, h: 0.375, fill: { color: SOFT_BLUE } });
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0.18, w: 0.12, h: 5.07, fill: { color: AMBER } });

  s.addText("TAKE-HOME MESSAGES", {
    x: 0.4, y: 0.25, w: 9.2, h: 0.5, fontSize: 22, bold: true, color: WHITE, align: "center"
  });

  const messages = [
    { num: "1", msg: "HDP is a spectrum — gestational HTN, preeclampsia, eclampsia, HELLP, and superimposed PE each carry distinct risk profiles and require tailored management.", color: TEAL },
    { num: "2", msg: "Etiopathogenesis is driven by a two-stage model: failed trophoblast invasion (Stage 1) → anti-angiogenic factor release causing endothelial dysfunction (Stage 2). Novel molecular targets include miRNAs, heparan sulfate, and HIF-1α.", color: AMBER },
    { num: "3", msg: "Severe features demand immediate action: IV antihypertensives within 30–60 min, MgSO₄ for seizure prophylaxis, and delivery as definitive treatment.", color: DANGER_RED },
    { num: "4", msg: "PPCM screening: all HDP patients, especially severe PE (OR 13.33), should be evaluated for peripartum cardiomyopathy with any cardiorespiratory symptoms.", color: MINT },
    { num: "5", msg: "Pregnancy is a cardiovascular stress test. Women with prior HDP have 2–8× elevated long-term CVD risk — postpartum risk counselling is mandatory.", color: "A569BD" },
  ];

  messages.forEach((msg, i) => {
    s.addShape(pres.ShapeType.ellipse, { x: 0.4, y: 0.95 + i * 0.88, w: 0.38, h: 0.38, fill: { color: msg.color } });
    s.addText(msg.num, { x: 0.4, y: 0.95 + i * 0.88, w: 0.38, h: 0.38, fontSize: 13, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addText(msg.msg, { x: 0.9, y: 0.95 + i * 0.88, w: 8.8, h: 0.82, fontSize: 10.5, color: LIGHT_GREY });
  });

  s.addText("Symposium on Hypertensive Disorders of Pregnancy  |  May 2026  |  For Postgraduate Residents", {
    x: 0.2, y: 5.27, w: 9.6, h: 0.3, fontSize: 8.5, color: LIGHT_GREY, align: "center"
  });
}

// ─── WRITE FILE ───────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/hdp-symposium/HDP_Symposium_2026.pptx" })
  .then(() => console.log("SUCCESS: Presentation written to /home/daytona/workspace/hdp-symposium/HDP_Symposium_2026.pptx"))
  .catch(err => { console.error("ERROR:", err); process.exit(1); });
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.